Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | THOR: erdafitinib in metastatic urothelial cancer with FGFR alterations

Yohann Loriot, MD, PhD, Gustave Roussy, Villejuif, France, provides an overview of the Phase III THOR trial (NCT03390504), which assessed erdafitinib, a pan-FGFR tyrosine kinase inhibitor, in patients with FGFR-mutant advanced or metastatic urothelial cancer (mUC). Patients were randomized to receive erdafitinib or chemotherapy, and erdafitinib resulted in superior overall-survival (OS), progression-free survival (PFS), and overall response rate (ORR). No new safety indications were additionally reported. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.